Join the Australian pavilion at the China Medical Equipment Fair
AusBiotech seeks your expression of interest to join the Australian delegation to the 73rd China International Medical Equipment Fair (CMEF) in May 2015. It is said to be the Asia-Pacific’s largest exhibition, with around 2700 exhibitors and 80,000 visitors.
Opportunities now exist for Australian companies and research organisations to participate at the Australian Pavilion at CMEF, to be held in Shanghai, China, from 15-18 May 2015.
CMEF services the entire value chain for the medical devices market. Visitors will include decision-makers, medical doctors, surgeons, procurement specialists from hospitals, distributors and agents of medical equipment and devices, technicians, research institutes and clinical laboratories. Further details regarding the fair can be viewed here.
The Australia Pavilion will offer exhibiting companies more than just an exhibition space - it will provide total support. The recognisable Brand Australia images, shared services, informal meeting areas, meeting rooms and reception counters will ensure you maximise your chances of achieving a successful outcome at this major event. Pricing will be confirmed early in the New Year.
AusBiotech is now seeking expressions of interest to attend this major event and will create various packages at affordable rates for companies interested in taking up this opportunity. To express your interest or for further information on the Australian delegation to CMEF, please contact Kirsty Grimwade, Event Manager AusBiotech, by calling (03) 9828 1406 or emailing kgrimwade@ausbiotech.org.
The delegation to CMEF is to be held immediately prior to Asia Biotech Invest 2015, from 19-21 May in Hong Kong. Timing has been arranged for delegates to be able to travel directly from CMEF to the Hong Kong investment meeting.
Austrade will be offering business matching services during CMEF and is planning a medical mission to China (tentatively 12-14 May) and a gala dinner during CMEF (tentatively 15 May). Information from Austrade regarding these fee-for-service options will be circulated separately
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...
A pre-emptive approach to treating leukaemia relapse
The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...
Long COVID abnormalities appear to resolve over time
Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...
